Aclaris posts Q1 net loss of $28.2M; delays PsA and AD trial data timelines

Aclaris Therapeutics, Inc.

2023-Q1 EPS reported -$0.42 revenue$2,528,000

Net loss widened to $28.2M from $18.8M YoY; revenue rose to $2.5M on higher licensing royalties.
Cash, cash equivalents and marketable securities $204.4M; ATM raised $26.7M net in April, extending runway through end-2025.
Zunsemetinib RA Phase 2b data guided to Q4 2023; PsA Phase 2a data delayed to H1 2024 (from YE 2023) due to slow European enrollment.
ATI-1777 AD Phase 2b data now expected H2 2023 (from mid-year) after protocol expansion to include milder disease.
ATI-2138 MAD data on track for H2 2023; ulcerative colitis selected as first development target.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aclaris Therapeutics, Inc. reported the first quarter of 2023 results: revenue $2.5 million, net income Net loss was $28.2 million.

Period: the first quarter of 2023
Revenue: $2.5 million
Net income: Net loss was $28.2 million
Result: reported results

Exact text from the filing

Financial Results First Quarter 2023 ● Net loss was $28.2 million for the first quarter of 2023 compared to $18.8 million for the first quarter of 2022. ● Total revenue was $2.5 million for the first quarter of 2023 compared to $1.5 million for the first quarter of 2022. The increase was driven primarily by higher licensing revenues from royalties earned on

View on SEC.gov

Browse all earnings releases →

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-008380

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.